<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Multipotent retinoid conjugate -crRASP</title>
  <link rel="stylesheet" href="/assets/css/base.css">
  <link rel="stylesheet" href="/assets/css/style.css">
  <link rel="stylesheet" href="/assets/css/constants.css">
</head>
<body>
    
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Novel Pharmaceutical Substance</title>
    <link rel="stylesheet" href="style.css">
</head>
<body>
    <nav>
        <div class="container">
            <a href="/#home">crRASP</a>
          </div>
    </nav>
    <header>
        <div id="home" class="container">
          <img class="top-right" src="assets/images/rasp.png" alt="crRASP Chemical formula">
          <p>innovate with</p>
          <h1><b>crRASP</b></h1>
          <p>A novel all-trans-retinoic acid conjugate against</p>
    
          <div class="fragments">
            <div id="fragment1">Psoriasis</div>
            <div id="fragment2">Acne</div>
            <div id="fragment3">Acute Promyelotic Leukemia</div>
            <div id="fragment4">Skin Cancer</div>
          </div>
        </div>
      </header>

    <section id="biological-profile" class="biological-profile">
        <div class="container">
            <h2>Biological profile</h2>
            <p>A multipotent conjugate of naturally occurring all-trans-retinoic acid and the polyamine spermine:</p>
            <ul>
                <li class="list-item">
                    <h3>not toxic or teratogenic</h3>
                    <!-- <p>not toxic or teratogenic</p> -->
                </li>
                <li class="list-item">
                    <h3>not phototoxic</h3>
                </li>
                <li class="list-item">
                    <h3>not mutagenic</h3>
                </li>
                <li class="list-item">
                    <h3>does not induce chromosome aberration</h3>
                </li>
            </ul>

        </div>
    </section>

    <section id="synthesis" class="synthesis">
        <div class="container">
            <h2>Synthesis</h2>
            <p>Two-step, high-yielding, fast & easy to perform at ambient temperature process</p>
            <ul>
                <li class="list-item">
                    <h3>Readily upscaled</h3>
                </li>
                <li class="list-item">
                    <h3>Atom economic</h3>
                </li>
                <li class="list-item">
                    <h3>Analytical grade</h3>
                </li>
            </ul>

        </div>
    </section>
    <section id="intellectual-property" class="intellectual-property">
        <div class="container">
            <h2>Intellectual property</h2>
            <p>RASP is a patented and secured compound:</p>
            <ul>
                <li class="list-item">Crystalline Forms for salts of N1,N12-DI(all-trans-retinoyl)spermine, Processes for their production and pharmaceutical compositions thereof. 
                    <br><a href="https://data.epo.org/publication-server/document?iDocId=6638572" target="_blank">EP3878840/15-09-2021.</a>
                        <span style="font-weight: bold;">Patent pending.
                </li>
                <li class="list-item">Κρυσταλιλκές μορφές της Ν1,Ν12-ΔΙ(all-trans-Ρετινοϋλο)Σπερμίνης, Διεργασίες για την παραγωγής τους και φαρμακευτικές συνθέσεις αυτών.<br>GR20200100131/10-03-2020. 
                    <span style="font-weight: bold;">Patent granted.
                </li>

        </div>
    </section>
    <section id="scientific-evidence" class="scientific-evidence">
        <div class="container">
            <h2>Scientific evidence</h2>
            <ul>
                <li class="list-item">RASP, administered orally at 50 mg/Kg to rats over two generations, showed no adverse effects on growth, characteristics, reflexes, or organ health[4].</li>
                <li class="list-item">In a comparative in vivo study, RASP showed four times more potent anti-inflammatory effects on rat paw oedema compared to tretinoin[2].</li>
                <li class="list-item">In an in vitro study, it was observed that RASP exhibited potent inhibitory effects on lipoxygenase, the crucial components of a biochemical pathway with a significant involvement in inflammation and immune response[2].</li>
                <li class="list-item">RASP significantly inhibits the production of IL-2 and IFN-γ by CD4+ and CD8+ cells, in contrast to the presently available retinoids, including tretinoin, and their isomers or esters. This suggests that RASP may have potential as an immunosuppressant drug[6].</li>
                <li class="list-item">Tretinoin and RASP both dose-dependently inhibited angiogenesis in the chicken embryo chorioallantoic membrane model, but RASP was more effective and could be used in a wider dose range due to lower toxicity compared with Tretinoin[3].</li>
                <li class="list-item">Both tretinoin and RASP decreased the number of HUVEC and prostate cancer cells in a dose-dependent manner. RASP was less cytotoxic than tretinoin on HUVEC cells, but more effective and potent on prostate cancer cells[3].</li>
                <li class="list-item">RASP inhibits RNase P, a key enzyme in protein synthesis at lower concentrations than retinoids. This suggests that RASP may be a more effective treatment for skin conditions that require increased protein synthesis such as psoriasis[1].</li>
                <li class="list-item">RASP has been shown to be effective against cancer. It works by regulating the expression of genes and miRNAs that are involved in apoptosis and the cell cycle[5].</li>
            </ul>
        </div>
    </section>
    <section id="research-publications" class="research-publications">
        <div class="container">
            <h2>Research Publications</h2>
            <ol>
                <li class="list-item">G. Magoulas, D. Papaioannou, E. Papadimou, D. Drainas “Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity“ European Journal of Medicinal Chemistry 44 (2009) 2689–2695.</li>
                <li class="list-item">D. Hadjipavlou-Litina, G.E. Magoulas, S.E. Bariamis, D. Drainas, K. Avgoustakis, D. Papaioannou “Does conjugation of antioxidants improve their antioxidative/anti-inflammatory  potential?” Bioorganic & Medicinal Chemistry 18 (2010) 8204–8217.</li>
                <li class="list-item">D. Vourtsis, M. Lamprou, E. Sadikoglou, A. Giannou, O. Theodorakopoulou, E. Sarrou, G. Magoulas, S. Bariamis, C. Athanassopoulos, D. Drainas, D. Papaioannou, E. Papadimitriou “Effect of an all-trans-retinoic acid conjugate with spermine on viability of human prostate cancer and endothelial cells in vitro and angiogenesis in vivo” European Journal of Pharmacology 698 (2013) 122-130.</li>
                <li class="list-item">T. Petridis, D. Giannakopoulou, V. Stamatopoulou, K. Grafanaki, C. Kostopoulos, H. Papadaki, C. Malavaki, N. Karamanos, S .Douroumi, D. Papachristou, G. Magoulas, D. Papaioannou, and D. Drainas “Investigation on Toxicity and Teratogenicity in Rats of a Retinoid-Polyamine Conjugate with Potent Anti-Inflammatory Properties” Birth Defects Research (Part B) 107 (2016) 32–44.</li> 
                <li class="list-item">K. Grafanaki, I. Skeparnias, C. Kontos, D. Anastasakis, A. Korfiati, G. Kyriakopoulos, K. Theofilatos, S. Mavroudi, G. Magoulas, D. Papaioannou, A. Scorilas, C. Stathopoulos, D. Drainas “Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes” Pharmacogenomics  J. 21 (2021) 638-648; https://doi.org/10.1038/s41397-021-00241-9</li>
                <li class="list-item">D. Papaioannou, D. Drainas and D. Tsambaos, WO 2004/018001 A1; US 7,517,913 B2</li>
            </ol>
        </div>
    </section>
    <section id="contact-us" class="cta">
        <div class="container">
            <h2>Do you have a question, a partnership or a licensing proposal?</h2>
            <p>Please email us at:</p>
            <p>contact [at] cr-rasp [dot] eu</p>
        </div>
    </section>
    <footer>
        <div class="container">
          <h2 class="grid-item header-grid-item"><b>crRASP</b></h2>
          <p class="grid-item sitemap-grid-item">
            <a href="/#home">Home</a> · 
            <a href="/#biological-profile">Biological Profile</a> · 
            <a href="/#synthesis">Synthesis</a> · 
            <a href="/#intellectual-property">Intellectual Property</a> · 
            <a href="/#scientific-evidence">Scientific Evidence</a> · 
            <a href="/#research-publications">Research Publications</a> · 
          </p>
          <small class="grid-item copyright-grid-item">
            &copy; Copyright 2023 RASP inventors − All Rights Reserved
          </small>
        </div>
    </footer>

</body>
</html>